Date:4/6/2011

to commercialize DIFICID, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, the ability of Optimer to adequately prepare for the launch of DIFICID in the U.S. and of Cubist and Optimer to work together effectively on the commercial launch, the parties' ability to successfully collaborate with one another under the co-promotion agreement regarding sales and marketing plans and strategy, the parties' ability to terminate the co-promotion agreement, existing competition for DIFICID in the U.S., the development of alternative treatments for or means of preventing CDI, whether and when regulatory authorities will review or approve Optimer's NDA for DIFICID on expected timelines, or at all, whether healthcare professionals will prescribe DIFICID, if approved, whether DIFICID will receive reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on hospital formularies, the timing of payments by Optimer under the co-promotion agreement, the timing and amount of payments to be received by Cubist, Optimer's ability to successfully recruit and retain sales and marketing personnel, Optimer's ability to successfully manage a sales and marketing organization and other the risks detailed in each of Optimer's and Cubist's  most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings.

Forward-looking statements speak only as of the date of this release, and neither Cubist nor Optimer undertakes any obligation to update or revise these statements,

Contacts

Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736

Canale Communications, Inc.
J
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS